BMRN icon

BioMarin Pharmaceuticals

57.29 USD
-1.08
1.85%
At close Jul 18, 4:00 PM EDT
After hours
57.11
-0.18
0.31%
1 day
-1.85%
5 days
-1.33%
1 month
3.71%
3 months
-2.32%
6 months
-8.38%
Year to date
-13.84%
1 year
-31.26%
5 years
-56.28%
10 years
-61.58%
 

About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Employees: 3,040

0
Funds holding %
of 7,321 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

85% more first-time investments, than exits

New positions opened: 102 | Existing positions closed: 55

39% more repeat investments, than reductions

Existing positions increased: 239 | Existing positions reduced: 172

11% more call options, than puts

Call options by funds: $97.7M | Put options by funds: $87.7M

8% more funds holding

Funds holding: 534 [Q4 2024] → 576 (+42) [Q1 2025]

7% more capital invested

Capital invested by funds: $12B [Q4 2024] → $12.8B (+$783M) [Q1 2025]

0.35% less ownership

Funds ownership: 96.11% [Q4 2024] → 95.76% (-0.35%) [Q1 2025]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$78
36%
upside
Avg. target
$98
72%
upside
High target
$113
97%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
JP Morgan
Jessica Fye
97%upside
$113
Overweight
Maintained
14 Jul 2025
Goldman Sachs
Salveen Richter
82%upside
$104
Buy
Maintained
5 May 2025
Citigroup
David Lebovitz
36%upside
$78
Neutral
Maintained
2 May 2025

Financial journalist opinion

Based on 12 articles about BMRN published over the past 30 days

Positive
Zacks Investment Research
3 days ago
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
Positive
Zacks Investment Research
3 days ago
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
The consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
Neutral
The Motley Fool
3 days ago
Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money
Though volatility is inherent in Wall Street, some years are more of a roller-coaster ride than others.
Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money
Positive
Zacks Investment Research
5 days ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Positive
Zacks Investment Research
1 week ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Positive
Zacks Investment Research
1 week ago
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
Positive
Zacks Investment Research
1 week ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Positive
CNBC Television
1 week ago
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Neutral
PRNewsWire
2 weeks ago
BioMarin Announces Completion of Acquisition of Inozyme
SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million.
BioMarin Announces Completion of Acquisition of Inozyme
Positive
Zacks Investment Research
3 weeks ago
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Charts implemented using Lightweight Charts™